Department of Surgery, Central Michigan University College of Medicine, Mt Pleasant, Mich.
Department of Pulmonary and Critical Care Medicine, New York Presbyterian-Weill Cornell Medicine, New York, NY.
J Thorac Cardiovasc Surg. 2023 Aug;166(2):336-344.e2. doi: 10.1016/j.jtcvs.2022.10.051. Epub 2022 Nov 14.
Lung cancer screening-associated complications are often quoted as one of the major barriers for wider screening adoption. A detailed analysis of the National Lung Screening Trial dataset was performed to extrapolate the safety of lung cancer screening.
Lung cancer screening-associated invasive procedures and their related complications were analyzed using the National Lung Screening Trial dataset. Factors associated with 90-day postprocedure complications per patient were analyzed with logistic-regression multivariable analysis.
Major complications rate in patients undergoing low-dose computed tomography screening who were diagnosed with lung cancer was 10.2% compared with only 0.04% for patients without lung cancer. Low-dose computed tomography screening, compared with chest radiography, led to major complications in an excess of only 3.5 per 10,000 patients without lung cancer. Among 25,633 patients without lung cancer who underwent low-dose computed tomography screening, 45 developed 90-day postprocedure complications (71 total complications). The most common were pneumothorax (n = 29; 41%), postprocedure hospitalization (n = 6; 8.5%), and infection/fever requiring antibiotics (n = 5; 7%). Cardiac/respiratory arrest occurred in less than 1 in 10,000 low-dose computed tomography-screened patients without lung cancer. On multivariable analysis, pulmonary comorbidity (confidence interval, 1.00-3.37) and procedure type (thoracoscopy [confidence interval, 2.04-10.64] or thoracotomy [confidence interval, 2.38-8.93]) were associated with postprocedure complications in patients without lung cancer. Randomization arm (low-dose computed tomography vs chest x-ray) was not a significant factor (confidence interval, 0.89-1.37).
It is more informative to report procedural complications in patients not found to have cancer as the true screening-associated risk. Only 4 in 10,000 of patients undergoing low-dose computed tomography screening but not found to have lung cancer will have major complications. Permanent or debilitating complications are exceedingly rare.
肺癌筛查相关并发症常被认为是广泛采用筛查的主要障碍之一。对国家肺癌筛查试验数据集进行了详细分析,以推断肺癌筛查的安全性。
利用国家肺癌筛查试验数据集分析肺癌筛查相关的有创性操作及其相关并发症。使用逻辑回归多变量分析,分析每位患者与 90 天术后并发症相关的因素。
与未患肺癌的患者相比,在接受低剂量 CT 筛查且被诊断为肺癌的患者中,主要并发症的发生率为 10.2%,而未患肺癌的患者为 0.04%。与胸部 X 线摄影相比,低剂量 CT 筛查导致每 10000 例无肺癌患者出现额外的 3.5 例以上的主要并发症。在 25633 例未患肺癌且接受低剂量 CT 筛查的患者中,45 例出现 90 天术后并发症(共 71 例并发症)。最常见的是气胸(n=29;41%)、术后住院(n=6;8.5%)和需要抗生素的感染/发热(n=5;7%)。在未患肺癌的低剂量 CT 筛查患者中,心脏/呼吸骤停的发生率不到每 10000 例的 1 例。多变量分析显示,肺部合并症(置信区间,1.00-3.37)和操作类型(胸腔镜[置信区间,2.04-10.64]或开胸手术[置信区间,2.38-8.93])与无肺癌患者术后并发症相关。随机分组(低剂量 CT 与胸部 X 射线)不是一个显著因素(置信区间,0.89-1.37)。
报告未发现癌症的患者的手术并发症更具信息性,因为这是真正与筛查相关的风险。在接受低剂量 CT 筛查但未发现肺癌的患者中,每 10000 例患者中只有 4 例会出现严重并发症。永久性或致残性并发症极为罕见。